ArticleAsia Pacific journal of clinical nutrition2026
Exploring key genes in NAFLD linked to glutamine metabolism: A comprehensive analysis combining multi-omics, machine learning and SHAP.
Article in Asia Pacific journal of clinical nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesNon-alcoholic fatty liver disease (NAFLD) is a prevalent liver condition glob-ally, with an escalating incidence and a strong association with various metabolic disorders, thus presenting a significant public health challenge. Currently, there is a scarcity of effective preventive or therapeutic methods for NAFLD. This study used multi-omics, machine learning (ML), and SHAP comprehensive analysis to explore NAFLD-related metabolites and genes, hoping to provide new insights. METHODS AND STUDY
designWe initially conducted MR analysis on 1,400 serum metabolites and two NAFLD datasets, identifying gluta-mine as causally linked to NAFLD. In single-cell RNA sequencing, hepatocytes were categorized into high-synthesis and low-synthesis glutamine groups for cell communication analysis. We extracted differentially expressed genes from these two groups and performed GO and KEGG enrichment analysis. Further screening of these genes was followed by the application of LASSO regression to identify hub genes for ML. We constructed the ML model using Catboost, NGboost, and XGboost algorithms. Finally, we employed the SHAP method to interpret the model, identifying key genes with significant model contributions.
resultsMR analysis demonstrated that the glutamine-to-alanine ratio and levels of 1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) were associated with a reduced incidence of NAFLD. We identified 19 hub genes for ML, with validation set AUCs of 0.83 for Catboost, 0.82 for NGboost, and 0.86 for XGboost. The SHAP analysis highlighted ASL, LGALS1, and GLUL as genes with the contributed significantly to the models.
conclusionsOur MR findings suggest that specific metabolites may lower the risk of NAFLD. A comprehensive analysis underscores the significant role of glutamine metabolism and related genes in NAFLD pathogenesis, offering new potential targets for NAFLD diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.